logo
Share SHARE
FONT-SIZE Plus   Neg

Novartis' Lung Disease Drug QVA149 Meet Primary Endpoints In Phase III Studies

Swiss pharmaceutical giant Novartis AG (NVS: Quote) on Monday said its first three QVA149 Phase III studies in the treatment of chronic obstructive pulmonary disease or COPD all met their primary endpoints.

QVA149, a bronchodilator with dual mode of action, is Novartis' third innovation in its Breezhaler single dose dry powder inhaler.

According to the company, the SHINE, BRIGHT and ENLIGHTEN studies demonstrate the potential of QVA149 in the treatment of COPD. The studies are components of the IGNITE Phase III clinical trial program intended to form the basis for an NDA filing in COPD.

The results of SHINE met the primary endpoint by demonstrating the superiority in trough FEV of once-daily QVA149 compared to once-daily indacaterol or once-daily NVA237 in patients with moderate to severe COPD.

The results of BRIGHT demonstrated that patients experienced significantly better exercise endurance versus placebo and ENLIGHTEN showed that QVA149 was well tolerated with a safety and tolerability profile similar to placebo.

Tim Wright, Head of Development, Novartis Pharmaceuticals, said, "Meeting the primary endpoints in the IGNITE Phase III clinical trial program signals significant progress in establishing the potential of QVA149, which is expected to be the third innovative medicine in our strong COPD portfolio."

The company noted that the data from the IGNITE clinical trial program examining QVA149 in a number of settings will be submitted for presentation to a major medical congress later this year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Mixed signal solutions provider NXP Semiconductors N.V. (NXPI) agreed Sunday to acquire embedded processing solutions provider Freescale Semiconductor Ltd (FSL) in a cash an stock deal valued at about $16.7 billion, including Freescale's net debt of $4.9 billion. Get ahead of the market. For in-depth... Mitel Networks Corp. (MITL, MNW.TO) and Mavenir Systems (MVNR) announced a merger agreement in which Mitel will acquire all of the outstanding shares of Mavenir common stock in a cash and stock deal valued at approximately $560 million. Get ahead of the market. For in-depth analysis not... ISIS has renewed its death threat to employees of micro-blogging site Twitter, Inc., particularly its co-founder Jack Dorsey. The threats are in retaliation for Twitter blocking accounts which are affiliated to or support the Islamic State. Twitter has a policy of barring users from posting threats or using the service for furthering of illegal activities.
comments powered by Disqus
RELATED NEWS
Trade NVS now with 
Follow RTT